hotspot -WSS

hotspot

author：hotspot 2025-10-02 22:56:38 - browse：1

Adam's take main illustration — Molly Ferguson/STAT

Thoughts about Cytokinetics after Wednesday night’s financing announcement:

1. Management is raising $500 million at $51 per share, when the stock was at $45 per share before the aficamtem study readout in December. That’s shocking. Somehow, management has not only removed all the M&A premium from the stock, but much or most of aficamtem’s value, too.

2. Omecamtiv’s resurrection: Are you kidding me? No one thinks bringing back this heart failure drug is a good idea, except management. Making it worse, the terms of the Royalty Pharma loan are, again, shocking. All the risk is borne by Cytokinetics. Royalty, in fact, may do better if omecamtiv fails.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： TB outbreak tied to bone grafts underscores testing shortcomings

Wikipedia

WSS

An innovative path out of biotech’s “valley of death”

Lilly's Alzheimer's drug donanemab backed by FDA advisers

Where are patients getting their prescriptions for GLP

FDA reviewers ask if approval of Lilly’s Alzheimer’s drug should be restricted

GOP presidential candidates start declaring their loyalty

Novo acquires Inversago for up to $1 billion

knowledge

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

leisure time

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Target recalls 2.2 million additional candles due to laceration, burn hazards

State Dept. review finds Biden bears some blame for Afghanistan failures

'Disease catastrophe' looms in Sudan as health conditions deteriorate, medics warn

Guidelines to prevent youth baseball injuries need more muscle

Listen: Your guide to Wegovy's blockbuster heart study

Tori Bowie and the unacceptable rates of Black maternal death

CDC overhauls leadership of center that led response to Covid

Psychedelics group wrestles with new pharma identity

Kim Kardashian sparks debate on benefits of full

explore

Stephen Quake on the Chan Zuckerberg quest to conquer disease

ALS patient reclaims some autonomy thanks to wearable 'robot'

Cancer thrives by mutating. But sometimes, a mutation leaves it vulnerable

CDC overhauls leadership of center that led response to Covid

FDA reviewers ask if approval of Lilly’s Alzheimer’s drug should be restricted

Heat wave can put hearts into ‘oxygen debt,' lab experiment shows

hotspot

Wikipedia

focus

knowledge